Conclusion

These results confirmed the feasibility of managing airway clearance in COPD/ACOS with Simeox device. This technology may

contribute to lung function improvement without worsening fatigue or pain during chest physiotherapy.

Gender Diagnosis Medication LFT FEV1 (l) before and after sessions

Age

W 72 3D+ACOS ICS+LABA+LAMA 1.05/1.18 6(+++)

M 81 2C LABA+LAMA 1.58/1.72 5(++)

W 36 2B deficit A1AT LABA+LAMA 2.10/2.35 6(+++)

M 68 2D ICS+LABA+LAMA 1.25/1.58 6(++)

M 64 4D ICS+LABA+LAMA Roflumilast

0.58/0.80 6(+++)

M 72 3D LABA+LAMA 1.80/1.97 6(++)

M 81 2B LAMA 1.05/1.25 6(+++)

W 66 4D+ACOS ICS+LABA+LAMA Roflumilast

0.65/0.78 6(++)

W 64 3D+ACOS ICS+LABA+LAMA 0.84/0.98 6(+++)

M 62 2B+ACOS ICS+LABA 2.05/2.23 6(+++)

M 72 2D+ACOS ICS+LABA+LAMA 1.82/1.99 6(++)

W 79 2B LAMA 2.46/2.68 6(+++)

M 72 3C LABA+LAMA 1.88/2.01 6(+++)

M 62 4D LABA+LAMA Roflumilast

0.86/1.02 6(+++)

M 68 4D ICS+LABA+LAMA Roflumilast

1.10/1.28 6(+++)

Тable 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

Nbre of sessions (mucus clearance)

39